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Objective: Many patients with peripheral arterial occlusive disease who require a lower-limb bypass have no available
autologous saphenous vein (ASV) for the procedure and thus require a prosthetic graft. Expanded polytetrafluoroeth-
ylene (ePTFE) grafts are commonly used, but results with these prostheses have varied, especially when the distal
anastomosis is below the knee. However, there is increasing evidence that ePTFE grafts to which heparin has been bound
with use of covalent endpoint linkage provide better results. This nonrandomized study compared the performance of
these grafts with that of ASV conduits in the largest clinical series of heparin-bonded ePTFE graft implantations reported
so far.
Methods: The records of 350 patients who underwent a lower-limb bypass procedure that used either a heparin-bonded
ePTFE graft (n  240) or an ASV graft (n  110) were reviewed, and preoperative, operative, and follow-up data were
recorded. Kaplan-Meier analyses were used to calculate primary patency and limb salvage rates in the two graft groups;
results were compared by using log-rank testing.
Results: The primary patency rates at 1 year for the heparin-bonded ePTFE grafts were 92% for above-knee femoropop-
liteal (AK FP) bypasses, 92% for below-knee femoropopliteal (BK FP) bypasses, and 79% for femorocrural (FC)
applications. The corresponding 2-year rates were 83%, 83%, and 69%, respectively. In the ASV group, the 1-year primary
patency rates for AK FP, BK FP, and FC bypasses were 91%, 72%, and 69%, respectively; the 2-year rates were 80%, 72%,
and 64%, respectively. There were no significant differences in patency when AK FP, BK FP, or FC procedures were
considered separately. Two-year limb salvage rates in the heparin-bonded ePTFE graft group were 92%, 98%, and 87%,
respectively, for AK FP, BK FP, and FC bypasses; in the ASV group, the rates were 100%, 91%, and 96%, respectively. Two
infections occurred in patients given a heparin-bonded ePTFE graft.
Conclusion: In this large retrospective study, heparin-bonded ePTFE grafts had 1- and 2-year primary patency results that
were not significantly different from those for ASV grafts. Results in BK FP and FC applications were especially
promising. Randomized studies comparing the use of heparin-bonded ePTFE and ASV grafts in the treatment of
peripheral arterial disease are needed to substantiate our results. ( J Vasc Surg 2009;49:1210-6.)Autologous saphenous vein (ASV) is considered the
material of choice for crural bypasses to relieve symptoms or
avoid amputation in patients with peripheral arterial occlu-
sive disease, but many such patients have no available
good-quality vein for these procedures. The most widely
used synthetic conduit is expanded polytetrafluoroethylene
(ePTFE), which has provided patency results similar to
those achieved with a vein in some randomized studies of
above-knee (AK) procedures1-3 but generally disappoint-
ing results in below-knee (BK) applications. However,
there are indications that ePTFE grafts to which heparin
has been bound with use of a covalent endpoint linkage
method4,5 (GORE PROPATEN Vascular Graft; WL Gore
& Associates, Inc, Flagstaff, Ariz) may yield better results.
Although no randomized controlled studies of the heparin-
bonded ePTFE grafts have been reported, favorable out-
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1210comes have been achieved with these prostheses in several
series.6-11 Results in BK applications have been especially
encouraging.
In 2002, we began to use heparin-bonded ePTFE
grafts for both AK and BK applications, including femoro-
crural (FC) bypasses, in patients without an ASV suitable
for grafting. By the end of 2006, we had implanted 240 of
these prostheses (86 in AK FP, 57 in BK FP, and 97 in FC
applications). During this same period, 110 lower-limb
bypass procedures using ASV (12 AK FP, 48 BK FP, and 50
FC) were also performed in our unit. Here we report a
retrospective study that compared 1- and 2-year results in
patients given heparin-bonded ePTFE grafts with those in
patients given ASV grafts during the study period.
METHODS
Institutional review board approval for this investiga-
tion was deemed unnecessary because of its retrospective
nature. The study involved a review of the medical records
of all patients who underwent an AK or BK bypass for
peripheral arterial occlusive disease (Rutherford disease-
stage class 3) in our unit between August 2002 and
March 2006 and in whom either a heparin-bonded ePTFE
graft or an ASV graft (in situ, reversed, or nonreversed) was
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veins such as the lesser saphenous vein or brachial vein were
not considered. The following information was obtained
from the records: age, gender, smoking status, preoperative
Rutherford class, preoperative American Society of Anes-
thesiologists (ASA) score, previous revascularization proce-
dures, location of the distal anastomosis of the bypass
(bypass location), run-off score, operative complications,
follow-up visits (scheduled for 1 and 6 months postopera-
tively and yearly thereafter), time between the bypass pro-
cedure and the end of the observation period (February 1,
2007), death from any cause, graft occlusions, and major
amputations.
All follow-up examinations included assessments of
distal pulses during interval visits. Duplex ultrasonography
scan was performed in case of clinical problems, if pulses
were absent and routinely during the 1- and 2-years visits.
The medical records were checked specifically to ensure
that all living patients had returned for either a 2-year
follow-up visit or a follow-up visit within a month of
February 1, 2007, the end of the observation period. The
36 patients who did not meet these criteria (28 in the
heparin-bonded ePTFE graft group and 8 in the ASV graft
group) were contacted and asked to make a follow-up visit.
Twenty-one of the 36 did so; for the remaining 15 themost
recent follow-up data were obtained by telephone or from
the records of their general practitioner.
Primary graft patency was defined as blood flow
Table I. Patients’ preoperative and operative characteristic
Characteristic
Heparin-bonded ePT
(n  240)
Mean age (years) (range) 70.4 (41-92
Male/female 161 (67%)/79 (
Smokers 149 (62%)
Preoperative Rutherford class
3 63 (26%)
4 60 (25%)
5 84 (35%)
6 17 (7%)
Acute ischemia 16 (7%)
Preoperative ASA score
1 12 (5%)
2 89 (37%)
3 127 (53%)
4 12 (5%)
Primary/redo bypass 154 (64%)/86 (
Bypass location
†
Above-knee FP (FP 1 or FP 2) 86 (36%)
Below-knee FP (FP 3) 57 (24%)
Femorocrural (FC) 97 (40%)
Femoral-tibiofibular trunk 10 (10%)
Femoral-anterior tibial artery 37 (38%)
Femoral-fibular artery 21 (22%)
Femoral-posterior tibial artery 29 (30%)
ePTFE, Expanded polytetrafluoroethylene; ASA, American Society of Anes
*Values are numbers (percentages) unless otherwise indicated.
†For FP 1, the anastomosis was between Hunter’s canal and the top of the p
for FP 3, it was distal of the knee articulation.
Bold values are P values .05.through a graft for which there had been either no reinter-vention to restore flow or reintervention only for an occlu-
sion or stenosis in a distal or proximal native vessel. Primary
graft patency ended if a graft occluded for any reason. Limb
salvage was defined as freedom from a major amputation,
taking into account only those patients with a critical
ischemia (Rutherford 4, 5, 6, or acute ischemia). Kaplan-
Meier methods were used to assess limb salvage and pri-
mary patency for AK FP, BK FP, and FC bypasses separately
in the heparin-bonded ePTFE and ASV graft groups. Log-
rank testing was used to compare results between groups. A
P value .05 was considered to represent a significant
difference.
RESULTS
Table I shows demographic, preoperative, and opera-
tive data, including specific bypass locations, in the 240
patients given a heparin-bonded ePTFE graft and the 110
given an ASV graft. There were no significant differences
between the two graft groups in the patients’ age or gender
distribution, Rutherford class distribution, or proportion of
smokers. Patients in the heparin-bonded ePTFE group
were significantly more likely to be undergoing a redo-
bypass (P  .003). Since there were significantly more AK
(P  .001) and less BK (P  .002) femoropopliteal by-
passes in the heparin-bonded ePTFE group, further com-
parisons were only made in the AK FP, BK FP, and FC
subgroups.
In the patients given a heparin-bonded ePTFE graft, a
raft Autologous saphenous vein graft
(n  110) P value
70.4 (36-88) .991
77 (70%)/33 (30%) .587
73 (66%) .440
28 (25%) .875
26 (24%) .783
43 (39%) .460
7 (6%) .568
6 (6%) .664
20 (18%) <.001
35 (32%) .339
53 (48%) .411
2 (2%) .156
88 (80%)/22 (20%) .003
12 (11%) .001
48 (44%) .002
50 (45%) .376
10 (20%) .065
19 (38%) .660
4 (8%) .085
17 (34%) .386
ogists; FP, femoropopliteal.
for FP 2, it was between the top of the patella and the knee articulation; ands*
FE g
)
33%)
36%)
thesiol
atella;thin-walled, 8-mm-diameter prosthesis was used in AK FP
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FC procedures. In patients given an ASV graft, the diame-
ter of the vein was at least 3 mm on duplex ultrasonography
scan, and this finding was confirmed at operation by cali-
bration with a 3-mm vascular dilator. All patients in the two
graft groups followed a similar postoperative antiplatelet
and anticoagulant regimen, including administration of
160 mg of aspirin per day. Warfarin therapy was continued
in patients who had been receiving it before surgery and
was started postoperatively in patients who underwent a
redo venous bypass.
There were two postoperative deep infections in the
synthetic-graft group, observed 5 and 6 months, respec-
tively, after surgery. One resolved after replacement of the
graft with an arterial homograft. The other was treated
successfully by drainage of a groin abscess and creation of a
rectus femoris muscle flap. There were no deep infections in
the vein group. No patient in either graft group had a late
perigraft seroma or hematoma requiring intervention. Two
in-hospital deaths occurred. One patient was treated first
for an infected aortobifemoral graft and required an addi-
tional BK FP bypass (using a heparin-bonded ePTFE graft)
the day after. Eventually, he died of a cardiogenic shock
1 week later. One patient who underwent an ASV bypass
Table II. Follow-up data, according to type of bypass gra
Characteristic Heparin-bond
Above-knee FP (AK FP) 86 (
Median follow-up time (month) (range)
†
25.3 (
Deaths from all causes 9 (
Occlusions 14 (
Amputations/2-year limb salvage rate 3/
1-year primary patency rate (95% CI) 92% (
SE 0
2-year primary patency rate (95% CI) 83% (
SE 0
Below-knee FP (BK FP) 57 (
Median follow-up time (month) (range)
†
24.6 (
Deaths from all causes 6 (
Occlusions 9 (
Amputations/2-year limb salvage rate 1/
1-year primary patency rate (95% CI) 92 (
SE 0
2-year primary patency rate (95% CI) 83 (
SE 0
Femorocrural (FC)
§
97 (
Median follow-up time (mo) (range)
†
18.8 (
Deaths from all causes 18 (
Occlusions 32 (
Amputations/2-year limb salvage rate 12/
1-year primary patency rate (95% CI) 79% (
SE 0
2-year primary patency rate (95% CI) 69% (
SE 0
ePTFE, Expanded polytetrafluoroethylene; CI, confidence interval; FP, fem
*Values are numbers (percentages) unless otherwise indicated.
†For living patients.
§See the footnote for Table I for descriptions of femorocrural bypasses.
Bold values are P values .05.died of an acute myocardial infarction. There was noincidence of a postoperative heparin-induced thrombo-
cytopenia.
Table II shows follow-up times and data on deaths,
occlusions, amputations, limb salvage, and primary patency
in the heparin-bonded ePTFE and ASV graft groups, ac-
cording to bypass location (AK FP, BK FP, and FC). Limb
salvage rates in the two graft groups at 2 years postopera-
tively showed no significant differences. Compared with
ASV grafts, the primary patency rates of the heparin-
bonded ePTFE grafts tended to be slightly better, however,
differences were not significant. One- and 2-year primary
patency rates for each of the bypass locations (AK FP, BK
FP, and FC) in the two graft groups are shown in Figs 1-3.
In Table III we made comparisons between subgroups
for each bypass location. Run-off score was similar for the
heparin-bonded ePTFE group and ASV group. Having
one, two, or three run-off arteries made no significant
difference in outcome (both groups together in AK FP, 2
year patency for 1, 2, and 3 run-off arteries were 71%, 81%,
and 86%, respectively, with P  .616; in BK FP 77%, 72%,
and 88%, respectively, with P  .228; in FC 65% for 1 and
65% for 2 run-off arteries with P .441). The distribution
of claudicants or patients with a critical ischemia was also
similar for both groups. In case of BK FP bypass for critical
d bypass location*
TFE graft Autologous saphenous vein graft P value
12 (11%) <.002
5) 28.5 (1-45) .631
1 (8%) .912
2 (17%) .804
0/100% .697
) 91% (51-99)
SE 0.043
) 80% (39-95) .804
SE 0.130
48 (44%) .001
7) 20.6 (1-46) .405
5 (10%) .879
14 (29%) .075
3/91% .054
) 72 (59-83)
SE 0.065
) 72 (59-83) .075
SE 0.065 .075
50 (45%) .376
8) 19.6 (1-44) .201
7 (14%) .075
17 (34%) .391
2/96% .157
) 69% (54-80)
SE 0.066
) 64% (48-76) .391
SE 0.071 .391
pliteal; SE, standard error.ft an
ed eP
36%)
1-4
10%)
16%)
92%
83-96
.031
72-90
.086
24%)
1-4
11%)
16%)
98%
81-97
.037
68-91
.057
40%)
1-4
19%)
33%)
87%
69-86
.042
58-78
.052
oropoischemia, results were better with the heparin-bonded
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(18%), an adjuvant technique was used, either a Miller cuff
(2 BK FP and 11 FC bypasses), a Taylor patch (2 BK FP and
3 FC), a Linton patch (1 AK FP, 2 BK FP, and 7 FC), or an
arteriovenous fistula at the distal anastomosis (15 FC). The
use of adjuvant techniques was left at the discretion of the
Fig 1. Kaplan-Meier analysis of primary patency of heparin-
bonded expanded polytetrafluoroethylene (hb-ePTFE) grafts and
autologous saphenous vein (ASV) grafts used in above-knee fem-
oropopliteal bypasses. The values below the x-axis represent the
number of limbs at risk at the start of the study and the start of each
time period. The vertical bars represent 95% confidence intervals.
The patency rates in the two graft groups were compared by using
log-rank testing.
Fig 2. Kaplan-Meier analysis of primary patency of heparin-
bonded expanded polytetrafluoroethylene (hb-ePTFE) grafts and
autologous saphenous vein (ASV) grafts used in below-knee fem-
oropopliteal bypasses. The values below the x-axis represent the
number of limbs at risk at the start of the study and the start of each
time period. The vertical bars represent 95% confidence intervals.
The patency rates in the two graft groups were compared by using
log-rank testing.surgeon and in our findings, these techniques did notinfluence outcome: within the heparin-bonded ePTFE
group there was no difference in patency using an adjuvant
technique or not (P  .930 in BK FP and P  .544 in FC
bypasses). In the FC-subgroup, in general, primary by-
passes performed better than redo-bypasses (P  .006). In
spite of this finding, the results of the heparin-bonded
ePTFE group were not affected by the greater incidence of
these redo-bypasses (61% redo bypasses in the heparin-
bonded ePTFE group vs 24% in the ASV group, P .015).
DISCUSSION
The Carmeda bioactive surface (CBAS; Carmeda, Up-
plands Väsby, Sweden) technology that is used to bind the
heparin to heparin-bonded ePTFE grafts immobilizes the
heparin molecule,5 thereby allowing the heparin on the graft
lumen to continue to bind antithrombin and thrombin
and thus retain its anticoagulant properties. The CBAS
process has been used successfully and safely for several
years to bind heparin to various medical devices, including
extracorporeal circuits for cardiopulmonary bypass proce-
dures12 and endovascular stents.13,14 Studies in animals
and ex vivo investigations in healthy human volunteers
showed that, compared with standard ePTFE vascular
grafts, CBAS-ePTFE grafts have less platelet deposition
after implantation4,15,16 and reduced thromobogenicity.17
In addition, a reduction in intimal hyperplasia at the distal
anastomosis of CBAS-ePTFE prostheses has been observed
in canine and baboon models.15,16 These effects may have
promoted short- and long-term graft patency in the pa-
tients in our series by impeding the development of
thrombi in the first months after implantation, as was
Fig 3. Kaplan-Meier analysis of primary patency of heparin-
bonded expanded polytetrafluoroethylene (hb-ePTFE) grafts and
autologous saphenous vein (ASV) grafts used in femorocrural
bypasses. The values below the x-axis represent the number of
limbs at risk at the start of the study and the start of each time
period. The vertical bars represent 95% confidence intervals. The
patency rates in the two graft groups were compared by using
log-rank testing.observed in the study by Dorigo et al.7 In addition, sus-
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ePTFE grafts may have mitigated the development of inti-
mal hyperplasia.
With respect to the number of patients enrolled, our
study is the largest clinical investigation of heparin-bonded
ePTFE grafts reported so far, as well as the largest compar-
ative assessment of the performance of these prostheses and
ASV grafts in patients requiring a lower-limb bypass. More-
over, only twoprevious series8,10 had a similarmean follow-up
time. Our 350-patient, 2-year study found that, compared
with ASV grafts, heparin-bonded ePTFE grafts had similar
results. When primary patency rates for AK FP, BK FP, and
FC procedures were evaluated separately, no significant
differences were observed between heparin-bonded ePTFE
grafts and ASV grafts. The limb salvage rates in the two
graft groups were also not significantly different for AK FP,
BK FP, and FC procedures separately. Other than two
infections (infection rate,1%), there were no graft-related
adverse events in patients given heparin-bonded ePTFE
grafts. Overall, our results, though not obtained in a random-
ized controlled trial, provide solid additional evidence that
heparin-bonded ePTFE grafts represent an important new
option in the treatment of peripheral arterial disease. The
promising results with the heparin-bonded ePTFE grafts
were especially seen in the FC subgroup: although more
Table III. Subgroup comparison in each bypass location*
Distribution
Hb- ePTFE ASV
Above-knee FP (AK FP) 86 (36%) 12 (11%)
3 run-off arteries 20 (23%) 3 (25%)
2 run-off arteries 44 (51%) 6 (50%)
1 run-off artery 22 (26%) 3 (25%)
Claudicants (RF 3) 48 (56%) 8 (67%)
Critical ischemia 38 (44%) 4 (33%)
Below-knee FP (BK FP) 57 (24%) 48 (44%)
3 run-off arteries 16 (28%) 12 (25%)
2 run-off arteries 28 (49%) 25 (52%)
1 run-off artery 13 (23%) 11 (23%)
Claudicants (RF 3) 11 (19%) 15 (31%)
Critical ischemia 46 (81%) 33 (69%)
Hb-ePTFE without 49 (86%)
With adjuvant technique 8 (14%)
Femorocrural (FC) 97 (40%) 50 (45%)
3 run-off arteries 2 (2%) 1 (2%)
2 run-off arteries 40 (41%) 25 (50%)
1 run-off artery 55 (57%) 24 (48%)
Claudicants (RF 3) 4 (4%) 5 (10%)
Critical ischemia 93 (96%) 45 (90%)
Hb-ePTFE without 60 (62%)
With adjuvant technique 37 (38%)
Worse results in redo’s:
Primary bypass 76 (52%)
Redo bypass 71 (48%)
More redo’s in Hb-ePTFE:
Redo bypass 59 (61%) 12 (24%)
Hb-ePTFE, Heparin-bonded expanded polytetrafluoroethylene; ASV, autol
*Values are numbers (percentages) unless otherwise indicated.
†Not enough data for the calculations.
Bold values are P values .05.likely to undergo a redo-operation, results were similarto these of the ASV grafts. The ASV remains our conduit
of choice, however, we became more stringent with
regard to the quality of the vein which means that we
switch to the heparin-bonded ePTFE when there is any
doubt.
Randomized studies have shown that standard ePTFE
grafts (no heparin bonding) yield patency results similar to
those of ASV when the distal anastomosis is above the
knee.1-3 In BK applications, however, results have been
much less encouraging. For example, a 2003 meta-analysis
found pooled 1- and 2-year primary patency rates of 59%
and 48%, respectively, for standard ePTFE grafts used in
infrapopliteal procedures.18 In comparison, the primary
patency rates for ASV grafts range from about 80% to 90%
at 1 year and from about 76% to 87% at 2 years.19-21 The
performance of heparin-bonded ePTFE grafts, although
not yet evaluated in a randomized study, has beenmarkedly
better. In our center, during the same period, standard
ePTFE grafts were used in 159 infrainguinal bypasses. In
the FC subgroup, the heparin-bonded ePTFE grafts (n 
97) performed significantly better than the standard ePTFE
group (n 45) (1- and 2-years primary patency of 75% and
67% vs 63% and 42%; P  .004). Five previous clinical
studies of the use of these prostheses in lower-limb bypasses
Patency in % (1 year/2 year)
P value Hb- ePTFE ASV P value
.001
.778 95/89 66/66 .287
.890 88/81 80/80 .811
.642 90/80 100/100 .412
.961 89/83 85/85 .813
.448 91/82 66/66 .418
.002
.990 100/92 83/83 .799
.330 88/73 70/70 .441
.776 90/90 62/31 .030
.102 100/85 93/93 .937
.981 90/76 61/55 .020
93/82 ¡
87/87 .930
.376
.994
† † †
.082 84/67 72/63 .653
.864 74/65 64/64 .832
.099 75/75 80/80 .937
.371 77/66 67/61 .739
82/69 ¡
70/70 .544
76/71 .006
67/52
.015 72/56 57/55 .500
saphenous vein; FP, femoropopliteal; RF, Rutherford.ogoushave been reported.6-10
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nonrandomized comparison of the performance of heparin-
bonded ePTFE grafts (n 37) and ASV grafts (n 37) in
infragenicular FP bypass procedures.8 In that investigation,
by Battaglia et al,8 there were no significant preoperative
differences between the two graft groups in demographic
characteristics, risk factors, concomitant disease, or number
of patients with severe vascular disease. Patients in the ASV
graft group did have a considerably poorer run-off status;
therefore, for the results analysis, the researchers divided
the patients in each group into low- and high-risk sub-
groups (high risk in case of only one run-off artery or in case
of Lercihe stage III or IV).
The overall 1-year primary patency rates in the heparin-
bonded ePTFE and ASV groups were 78% and 81%, respec-
tively (P not mentioned); the 2-year rates were 76% and
80% (P  .52). Among high-risk patients, ASV grafts
provided better 2-year patency results (72% vs 40%; P 
.01). Among low-risk patients, however, the 2-year patency
rates for the two graft types were almost identical (94% and
93%; P  .86). One graft infection developed in a patient
given a heparin-bonded ePTFE graft. The limb salvage
rates were 100% and 93% (P not mentioned) among low-
risk patients in the heparin-bonded ePTFE and ASV
groups, respectively, and 69% and 74% (P not mentioned)
among high-risk patients. Therefore, the results of Batta-
glia et al8 were similar to ours in showing no difference in
the performance of heparin-bonded ePTFE grafts and ASV
conduits.
The only prospective clinical investigation of heparin-
bonded ePTFE grafts described so far was a multicenter,
noncomparative trial in which the results were reported, as
in our study, according to the location of the distal anasto-
mosis of the bypass (ie, all bypass locations, AK FP, BK FP,
and FC).9,10 The 1-year primary patency rate for all bypass
locations combined (n  99 limbs) was 82%. For AK FP
bypasses, the 1-year primary patency rate was 84%; for BK
FP bypasses, 81%; and for FC bypasses, 74%. The 1-year
limb salvage rate for the 41 limbs in the series affected by
critical ischemia before surgery (both AK and BK bypasses)
was 87%.9 The 2-year primary patency rates in the series
were 74% for all bypass locations (n 153 limbs), and 76%,
73%, and 69%, respectively, for AK FP, BK FP, and FC
sites.10 The 2-year limb salvage rate was 90%. No periop-
erative complications occurred, and no patient had an
infection, perigraft seroma, prolonged anastomotic bleed-
ing, or postoperative development of heparin-induced
thrombocytopenia.
Randomized studies are needed to confirm our finding
that heparin-bonded ePTFE grafts provide 2-year primary
patency and limb salvage results not significantly different
from those of ASV grafts in lower-limb bypasses, even in
BK locations. The results in our large comparative series do
indicate, however, that heparin-bonded ePTFE grafts can
be used with confidence in patients requiring bypass sur-
gery for peripheral arterial occlusive disease. Moreover,
several aspects of the use of synthetic grafts, especially
avoidance of the greater complexity, larger and increasednumber of incisions, and longer operating time associated
with ASV procedures, may provide a quality-of-life benefit
in patients who need a lower-limb bypass.
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